
Currently out of the existing stock ratings of Thomas Shrader, 270 are a BUY (94.08%), 17 are a HOLD (5.92%).
Analyst Thomas Shrader, currently employed at BTIG, has had 40.86% of price targets met with an average potential upside of 46.68%, reached in 214 days on average.
Thomas Shrader has documented 546 price targets and ratings displayed on 58 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on HROW, Harrow Health.
Analyst best performing recommendations are on NERV (MINERVA NEUROSCIENCES).
The best stock recommendation documented was for NERV (MINERVA NEUROSCIENCES) on 3/9/2023. The price target of $7 was fulfilled within 62 days with a profit of $5.19 (286.74%), with a performance score of 46.25.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-Jan-2026
$91
$12.83 (16.41%)
$88
3 days ago
(12-Nov-2026)
Buy Since 02-Jun-2026
$108
$29.83 (38.16%)
$106
14 days ago
(01-Nov-2026)
0/3 (0%)
$33 (44.00%)
Buy Since 21-Jul-2019
$100
$21.83 (27.93%)
$110
17 days ago
(29-Oct-2026)
5/9 (55.56%)
$25.05 (33.42%)
215
Hold Since 18-May-2026
$91
$12.83 (16.41%)
$93
28 days ago
(18-Oct-2026)
1/3 (33.33%)
$23.06 (33.94%)
51
Buy Since 03-Sep-2024
$120
$41.83 (53.51%)
$115
28 days ago
(18-Oct-2026)
11/15 (73.33%)
$52.06 (76.63%)
188
Which stock is Thomas Shrader most bullish on?
Which stock is Thomas Shrader most reserved on?
What Year was the first public recommendation made by Thomas Shrader?